Please login to the form below

Not currently logged in
Email:
Password:

antidote

This page shows the latest antidote news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma

an antidote to life-threatening or uncontrolled bleeding.

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence, collaboration. 237.5. Portola Pharmaceuticals/  HealthCare Royalty Partners. AndexXa (andexanet alfa) - Factor Xa inhibitor antidote (phase IIIb/IV).

  • Deal Watch February 2016 Deal Watch February 2016

    merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Portola is also developing PRT 064445, which is an antidote designed to reverse the activity of factor Xa inhibitors and low molecular weight heparins. ... Idrabiotaparinux sodium has the same pentasaccharidic structure as idraparinux sodium but has an

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • How to be a patient

    We can therefore provide a service by offering impartial, code-compliant information as an antidote to the 'alt-med' lobby.  .

  • Ogilvy Healthworld Ogilvy Healthworld

    'We have a habit of divine discontent with our performance.It is an antidote to smugness.'So said David Ogilvy.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics